Overview

Anti-arrhythmic Therapy vs Catheter Ablation as First Line Treatment for AICD Shock Prevention

Status:
Terminated
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether catheter based ablation is better than conventional anti-arrhythmic drug (AAD) therapy for reducing recurrent shocks in patients with an implantable cardioverter defibrillator (ICD). The second purpose of the study is to determine the safety of catheter-based ablation and the effect on quality of life of patients. The study hypothesis is that catheter ablation is superior to AAD therapy in preventing recurrent ventricular arrhythmia in such subjects. This is a pilot trial which will provide data regarding recruitment potential and the feasibility of conducting a larger trial.
Phase:
Phase 4
Details
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Treatments:
Amiodarone
Anti-Arrhythmia Agents
Mexiletine
Procainamide
Sotalol